Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 10/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411477 | 0.88 | CNR1 (0.40) | KDM4ELMNANPSR1HSD17B10NEK2 | |
| SCHEMBL2405902 | 0.86 | FFAR4 (0.41) | FFAR4 | |
| SCHEMBL2406060 | 0.84 | DKK1 (0.42) | FFAR4 | |
| SCHEMBL2411198 | 0.83 | PIM1 (0.36) | FFAR4 | |
| SCHEMBL2405627 | 0.83 | CNR1 (0.38) | FFAR4 | |
| SCHEMBL2407113 | 0.83 | SMN1; SMN2 (0.44) | FFAR4 | |
| SCHEMBL2405635 | 0.83 | PIM2 (0.36) | FFAR4 | |
| SCHEMBL2408111 | 0.83 | PRKD1 (0.37) | FFAR4 | |
| SCHEMBL2406148 | 0.83 | HSD11B1 (0.38) | FFAR4 | |
| SCHEMBL2407614 | 0.82 | FFAR4 (0.42) | FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | KDM4E 1536/4885LMNA 3832/4885ALOX15 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.